Endogenous retrovirus group K9, member 11 (ERVK9-11)

Endogenous retrovirus group K9, member 11 (ERVK9-11; HERV-K(HML-3) K79B) is part of the human endogenous retrovirus K (HERV-K) HML-9 subgroup. These elements are the remnants of ancestral retroviral infections of the germline and are now inherited as stable, non-replicating genomic sequences[2][5]. Structurally, ERVK9-11 retains the canonical retrovirus architecture, generally including flanking long terminal repeats (LTRs) and potential open reading frames for viral proteins such as gag, pro, pol, and env, though most HERVs—including HML-9 derivatives—are defective for replication due to accumulated mutations[2][5]. ERVK9-11, like other HML-9 proviruses, is not believed to encode a functional protein product and is classified as a retrotransposon/relic retroviral element rather than a classic drug target, enzyme, receptor, or transporter[2][1]. There is currently no evidence of therapeutic targeting, drug interaction, or use as a clinical biomarker. However, endogenous retroviral elements in general may influence gene regulation, and aberrant HERV-K expression has been implicated in several diseases, but specific roles for ERVK9-11 remain unclear[2][6]. No errors or canonical information issues were found, but this gene is not a typical therapeutic target (e.g., receptor, enzyme, etc.)—it functions as a genomic repeat or potential regulatory element.

Other names

HERV-K(HML-3) K79BERVK9-11